Figure 2 | Scientific Reports

Figure 2

From: Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

Figure 2

Changes in mean best-corrected visual acuity (BCVA), expressed as logarithm of the minimal angle of resolution, during the 36-month anti-vascular endothelial growth factor treatment for macular neovascularization. The BCVA at 3 months was significantly different between the pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration (nAMD) (ANOVA, P = 0.031). However, there was no significant difference between the groups at 12, 24, and 36 months.

Back to article page